TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA® (pembrolizumab)

Dateline City: WALTHAM, Mass., and KENILWORTH, N.J. Clinical Trial Will Evaluate TESARO’s PARP Inhibitor with Merck’s Anti-PD-1 Therapy in Patients with Breast and Ovarian Cancers WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 – TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESARO’s niraparib plus Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in a Phase 1/2 clinical trial. Language: English read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news